Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Endometrial Cancer | Primary research

Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer

Authors: Jinhui Liu, Jie Mei, Siyue Li, Zhipeng Wu, Yan Zhang

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Endometrial cancer (EnCa) ranks fourth in menace within women’s malignant tumors. Large numbers of studies have proven that functional genes can change the process of tumors by regulating the cell cycle, thereby achieving the goal of targeted therapy.

Methods

The transcriptional data of EnCa samples obtained from the TCGA database was analyzed. A battery of bioinformatics strategies, which included GSEA, Cox and LASSO regression analysis, establishment of a prognostic signature and a nomogram for overall survival (OS) assessment. The GEPIA and CPTAC analysis were applied to validate the dysregulation of hub genes. For mutation analysis, the “maftools” package was used.

Results

GSEA identified that cell cycle was the most associated pathway to EnCa. Five cell cycle-related genes including HMGB3, EZH2, NOTCH2, UCK2 and ODF2 were identified as prognosis-related genes to build a prognostic signature. Based on this model, the EnCa patients could be divided into low- and high-risk groups, and patients with high-risk score exhibited poorer OS. Time-dependent ROC and Cox regression analyses revealed that the 5-gene signature could predict EnCa prognosis exactly and independently. GEPIA and CPTAC validation exhibited that these genes were notably dysregulated between EnCa and normal tissues. Lower mutation rates of PTEN, TTN, ARID1A, and etc. were found in samples with high-risk score compared with that with low-risk score. GSEA analysis suggested that the samples of the low- and high-risk groups were concentrated on various pathways, which accounted for the different oncogenic mechanisms in patients in two groups.

Conclusion

The current research construct a 5-gene signature to evaluate prognosis of EnCa patients, which may innovative clinical application of prognostic assessment.
Appendix
Available only for authorised users
Literature
1.
Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016;93(6):468–74.PubMed
2.
Suri V, Arora A. Management of endometrial cancer: a review. Rev Recent Clin Trials. 2015;10(4):309–16.PubMedCrossRef
3.
McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother’s cancer. Cancer. 2016;122(18):2787–98.PubMedCrossRef
4.
Bendifallah S, Ballester M, Darai E. Endometrial cancer: predictive models and clinical impact. Bull Cancer. 2017;104(12):1022–31.PubMedCrossRef
5.
Lee YC, Lheureux S, Oza AM. Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol. 2017;29(1):47–58.PubMedCrossRef
6.
Wu F, Shi X, Zhang R, Tian Y, Wang X, Wei C, et al. Regulation of proliferation and cell cycle by protein regulator of cytokinesis 1 in oral squamous cell carcinoma. Cell Death Dis. 2018;9(5):564.PubMedPubMedCentralCrossRef
7.
Guo Z, Wang Y, Yang J, Zhong J, Liu X, Xu M. KAI1 overexpression promotes apoptosis and inhibits proliferation, cell cycle, migration, and invasion in nasopharyngeal carcinoma cells. Am J Otolaryngol. 2017;38(5):511–7.PubMedCrossRef
8.
Sun J, Shi R, Zhao S, Li X, Lu S, Bu H, et al. Cell division cycle 45 promotes papillary thyroid cancer progression via regulating cell cycle. Tumour Biol. 2017;39(5):1010428317705342.PubMedCrossRef
9.
Zhang X, Feng H, Li Z, Guo J, Li M. Aspirin is involved in the cell cycle arrest, apoptosis, cell migration, and invasion of oral squamous cell carcinoma. Int J Mol Sci. 2018;19(7):2029.PubMedCentralCrossRef
10.
Shyam H, Singh N, Kaushik S, Sharma R, Balapure AK. Centchroman induces redox-dependent apoptosis and cell-cycle arrest in human endometrial cancer cells. Apoptosis. 2017;22(4):570–84.PubMedCrossRef
11.
Qiu H, Li J, Clark LH, Jackson AL, Zhang L, Guo H, et al. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer. Oncotarget. 2016;7(41):66809–21.PubMedPubMedCentralCrossRef
12.
Zhou Y, Wang K, Zhen S, Wang R, Luo W. Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21(Waf1/Cip1) and p27(Kip1). Taiwanese J Obstet Gynecol. 2016;55(6):847–51.PubMedCrossRef
13.
Tomczak K, Czerwinska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol. 2015;19(1a):A68–77.
14.
Toh H, Shirane K, Miura F, Kubo N, Ichiyanagi K, Hayashi K, et al. Software updates in the Illumina HiSeq platform affect whole-genome bisulfite sequencing. BMC Genomics. 2017;18(1):31.PubMedPubMedCentralCrossRef
15.
Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics. 2007;23(23):3251–3.PubMedCrossRef
16.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.PubMedCrossRef
17.
Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61(1):92–105.PubMedCrossRef
18.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98.PubMedPubMedCentralCrossRef
19.
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58.PubMedPubMedCentralCrossRef
20.
Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56.PubMedPubMedCentralCrossRef
21.
Zeng Z, Cheng J, Ye Q, Zhang Y, Shen X, Cai J, et al. A 14-Methylation-driven differentially expressed RNA as a signature for overall survival prediction in patients with uterine corpus endometrial carcinoma. DNA Cell Biol. 2020;39(6):975–91.PubMedCrossRef
22.
Liu J, Li S, Feng G, Meng H, Nie S, Sun R, et al. Nine glycolysis-related gene signature predicting the survival of patients with endometrial adenocarcinoma. Cancer Cell Int. 2020;20:183.PubMedPubMedCentralCrossRef
23.
24.
Stros M. HMGB proteins: interactions with DNA and chromatin. Biochem Biophys Acta. 2010;1799(1–2):101–13.PubMed
25.
Zhang Z, Chang Y, Zhang J, Lu Y, Zheng L, Hu Y, et al. HMGB3 promotes growth and migration in colorectal cancer by regulating WNT/beta-catenin pathway. PLoS ONE. 2017;12(7):e0179741.PubMedPubMedCentralCrossRef
26.
Gu J, Xu T, Huang QH, Zhang CM, Chen HY. HMGB3 silence inhibits breast cancer cell proliferation and tumor growth by interacting with hypoxia-inducible factor 1alpha. Cancer Manage Res. 2019;11:5075–89.CrossRef
27.
Yamada Y, Nishikawa R, Kato M, Okato A, Arai T, Kojima S, et al. Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis. J Hum Genet. 2018;63(2):195–205.PubMedCrossRef
28.
Liu J, Wang L, Li X. HMGB3 promotes the proliferation and metastasis of glioblastoma and is negatively regulated by miR-200b-3p and miR-200c-3p. Cell Biochem Funct. 2018;36(7):357–65.PubMedCrossRef
29.
30.
Wang Y, Hou N, Cheng X, Zhang J, Tan X, Zhang C, et al. Ezh2 Acts as a tumor suppressor in Kras-driven lung adenocarcinoma. Int J Biol Sci. 2017;13(5):652–9.PubMedPubMedCentralCrossRef
31.
Bohm J, Muenzner JK, Caliskan A, Ndreshkjana B, Erlenbach-Wunsch K, Merkel S, et al. Loss of enhancer of zeste homologue 2 (EZH2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells. J Cancer Res Clin Oncol. 2019;145(9):2227–40.PubMedPubMedCentralCrossRef
32.
Chen S, Pu J, Bai J, Yin Y, Wu K, Wang J, et al. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis. J Exp Clin Cancer Res. 2018;37(1):3.PubMedPubMedCentralCrossRef
33.
Oki S, Sone K, Oda K, Hamamoto R, Ikemura M, Maeda D, et al. Oncogenic histone methyltransferase EZH2: a novel prognostic marker with therapeutic potential in endometrial cancer. Oncotarget. 2017;8(25):40402–11.PubMedPubMedCentralCrossRef
34.
Ihira K, Dong P, Xiong Y, Watari H, Konno Y, Hanley SJ, et al. EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis. Oncotarget. 2017;8(8):13509–20.PubMedPubMedCentralCrossRef
35.
Gu Y, Zhang J, Guan H. Expression of EZH2 in endometrial carcinoma and its effects on proliferation and invasion of endometrial carcinoma cells. Oncol Lett. 2017;14(6):7191–6.PubMedPubMedCentral
36.
Krill L, Deng W, Eskander R, Mutch D, Zweizig S, Hoang B, et al. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2020;156(2):423–9.PubMedCrossRef
37.
Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, et al. Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biol Ther. 2020;21(2):147–56.PubMedCrossRef
38.
Xiu MX, Liu YM. The role of oncogenic Notch2 signaling in cancer: a novel therapeutic target. Am J Cancer Res. 2019;9(5):837–54.PubMedPubMedCentral
39.
Motooka Y, Fujino K, Sato Y, Kudoh S, Suzuki M, Ito T. Pathobiology of Notch2 in lung cancer. Pathology. 2017;49(5):486–93.PubMedCrossRef
40.
Devor EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, Lankes HA, Thaker P, et al. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;147(3):648–53.PubMedPubMedCentralCrossRef
41.
Zhou Q, Jiang H, Zhang J, Yu W, Zhou Z, Huang P, et al. Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the Stat3 pathway. Cancer Manage Res. 2018;10:6339–55.CrossRef
42.
Wu Y, Jamal M, Xie T, Sun J, Song T, Yin Q, et al. Uridine-cytidine kinase 2 (UCK2): a potential diagnostic and prognostic biomarker for lung cancer. Cancer Sci. 2019;110(9):2734–47.PubMedPubMedCentralCrossRef
43.
Shen G, He P, Mao Y, Li P, Luh F, Ding G, et al. Overexpression of Uridine-Cytidine Kinase 2 correlates with breast cancer progression and poor prognosis. J Breast Cancer. 2017;20(2):132–41.PubMedPubMedCentralCrossRef
44.
Yang K, Tylkowski MA, Huber D, Contreras CT, Hoyer-Fender S. ODF2 maintains centrosome cohesion by restricting beta-catenin accumulation. J Cell Sci. 2018;131(20).
45.
Colicino EG, Stevens K, Curtis E, Rathbun L, Bates M, Manikas J, et al. Chromosome misalignment is associated with PLK1 activity at cenexin-positive mitotic centrosomes. Mol Biol Cell. 2019;30(13):1598–609.PubMedPubMedCentralCrossRef
46.
Kierszenbaum AL, Rivkin E, Tres LL. Cytoskeletal track selection during cargo transport in spermatids is relevant to male fertility. Spermatogenesis. 2011;1(3):221–30.PubMedPubMedCentralCrossRef
47.
Wise HM, Hermida MA, Leslie NR. Prostate cancer, PI3K, PTEN and prognosis. Clin Sci. 2017;131(3):197–210.CrossRef
48.
Zhu YP, Sheng LL, Wu J, Yang M, Cheng XF, Wu NN, et al. Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer. Hum Pathol. 2018;78:28–35.PubMedCrossRef
49.
Yan LX, Liu YH, Xiang JW, Wu QN, Xu LB, Luo XL, et al. PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer. Int J Oncol. 2016;48(2):471–84.PubMedCrossRef
50.
Hu Q, Zhang B, Chen R, Fu C, Jun A, Fu X, Li J, Fu L, et al. ZFHX3 is indispensable for ERbeta to inhibit cell proliferation via MYC downregulation in prostate cancer cells. Oncogenesis. 2019;8(4):28.PubMedPubMedCentralCrossRef
51.
Chung TKH, Cheung TH, Yim SF, Yu MY, Chiu RWK, Lo KWK, et al. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. Gynecol Oncol. 2017;146(2):334–9.PubMedCrossRef
52.
Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843–52.PubMedPubMedCentralCrossRef
53.
Cheng J, Zheng G, Jin H, Gao X. Towards tyrosine metabolism in esophageal squamous cell carcinoma. Comb Chem High Throughput Screen. 2017;20(2):133–9.PubMedCrossRef
54.
Chamberland JP, Moon HS. Down-regulation of malignant potential by alpha linolenic acid in human and mouse colon cancer cells. Fam Cancer. 2015;14(1):25–30.PubMedCrossRef
Metadata
Title
Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer
Authors
Jinhui Liu
Jie Mei
Siyue Li
Zhipeng Wu
Yan Zhang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01428-z

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

MAFG-AS1 aggravates the progression of pancreatic cancer by sponging miR-3196 to boost NFIX

Primary research

MicroRNA-138-5p targets the NFIB-Snail1 axis to inhibit colorectal cancer cell migration and chemoresistance

Primary research

Transgelin interacts with PARP1 in human colon cancer cells

Primary research

Identification of methylation-driven genes related to the prognosis of papillary renal cell carcinoma: a study based on The Cancer Genome Atlas

Primary research

FABP4 promotes invasion and metastasis of colon cancer by regulating fatty acid transport

Primary research

Targeting deubiquitinating enzyme USP26 by microRNA-203 regulates Snail1’s pro-metastatic functions in esophageal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits